Innovation Fund Denmark

Innobooster

Advanced Cancer Treatment via Non-invasive Electroporation

With a foundation in medical and engineering science, HHC Medical is developing a new technology for non-invasive chemotherapy delivery via electroporation.

In cancer treatment, electroporation enhances chemotherapy effectiveness and reduces the required dosage, leading to fewer side effects and a gentler treatment for patients.

HHC Medical’s mission is to make their technology accessible worldwide.

HHC Medical has previously received multiple grants from Innovation Fund Denmark. In 2022, the company joined Bio Innovation Institute’s Venture Lab, further strengthening their position as a pioneer in Health Tech.

HHC Medical

HHC Medical receives a 4.76 million DKK Innobooster grant from Innovation Fund Denmark to develop an electroporation device for cancer treatment.

Founded in 2019, HHC Medical has previously received support from Innovation Fund Denmark and Bio Innovation Institute. This new grant will support the development of the world’s first wireless, non-invasive electroporation device, set to revolutionize cancer treatment.

Electroporation is a technology that uses short electrical pulses to penetrate the cell membrane, creating small temporary pores that enhance the absorption of chemotherapy into cancer cells. This significantly increases treatment effectiveness while significantly reducing side effects.

Benefits of Electroporation in Cancer Treatment:

Targeted and precise therapy
Enhanced chemotherapy effectiveness
Reduced side effects

The goal is to make this treatment accessible worldwide and improve the quality of life for cancer patients.

Har du lyst til at høre mere?

Thomas Bjerre, Founder
Telefon: 50510200

Kontakt

Click here to add your own text

Innobooster

Advanced Cancer Treatment via Non-invasive Electroporation

HHC Medical

Better Cancer Diagnosis

The End for Uncertain Contracts

New Campus in Kalundborg

Har du lyst til at høre mere?